Abstract:We have recently characterized a unique CD8 T cell subset that expresses NKG2C, as well as multiple other natural killer cell markers. These NKG2C+ CD8 T cells demonstrate NK-like effector functions against various tumor targets, can be efficiently expanded and engineered using GMP-compatible techniques, and most importantly, display beneficial qualities unique to T and NK cells while minimizing the therapeutic deficits of each. NKG2C+ CD8 cells can be easily expanded using a genetically modified K562 feeder line and can be efficiently engineered via retroviral transduction. We genetically engineered NKG2C+ CD8 T cells to express an anti-CD19-28-z CAR construct to target B cell malignancies and compared effector functions of the CAR-engineered NKG2C+ CD8 T cells against CAR+NKG2C- (conventional) CD8 T cells and CAR+ NK cells in vitro and in vivo. We examined expansion, engineering efficiency, tumor control, and extent of cytokine release syndrome (CRS). We also engineered NKG2C+ CD8 T cells with a transgenic NY-ESO-1 TCR to target melanoma and compared the functional responses and efficacy of TCR-engineered NKG2C+ CD8 T cells against TCR-engineered conventional CD8 T cells. CAR+NKG2C+ CD8 T cells demonstrated superior in vitro effector function when compared to CAR+ conventional CD8 T cells and CAR+NK cells and did not upregulate characteristic T cell exhaustion markers, such as PD-1, TIM-3, and LAG-3. These CAR+NKG2C+ CD8 T cells demonstrated superior control of a CD19+ NALM6 tumor model in NRG mice, which was further enhanced with administration of IL-15. CAR+NKG2C+ CD8 T cells with IL-15 demonstrate dramatic and enhanced persistence, as well as superior cytotoxicity and activation in vivo when compared to CAR+ conventional CD8 T cells and CAR+ NK cells. Using a SCID-beige CRS mouse model, we observed reduced CRS in mice treated with CAR+ NKG2C+ CD8 T cells than in mice treated with CAR+ conventional CD8 T cells, with lower levels of proinflammatory cytokines and minimal expansion of murine myeloid subsets. Similarly, TCR-engineered NKG2C+ CD8 T cells demonstrated enhanced tumor control and in vivo persistence in an A375 melanoma-bearing NRG mouse model compared to TCR-engineered conventional CD8 T cells. We have successfully demonstrated that CAR- or TCR-engineered NKG2C+ CD8 T cells have superior anti-tumor efficacy, in vitro and in vivo, to conventional CD8 T cell and NK cell counterparts due to their innate tumor killing and greater in vivo persistence. These cells mediate less CRS and provide a safer alternative to traditional engineered T cell therapeutics. Ultimately, our NKG2C+ CD8 T cells represent a unique platform for engineered T cell therapies to target both solid tumors and hematologic malignancies, that is easily expanded ex vivo, does not require CD4 T cells for in vivo persistence, and is resistant to exhaustion. Citation Format: Kyle Lupo, M. Kazim Panjwani, Anthony Daniyan, Christopher Klebanoff, Katharine Hsu. Engineered NK-like NKG2C+ CD8 T cells mediate superior anti-tumor efficacy over conventional CD8 T cells and NK cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5233.

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3 show enhanced antitumor activity

NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity

Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen

A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells

Abstract 1318: Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

A Soluble NK-CAR Mediates the Specific Cytotoxicity of NK Cells toward the Target CD20<SUP>+</SUP> Lymphoma Cells

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

Abstract 5233: Engineered NK-like NKG2C+ CD8 T cells mediate superior anti-tumor efficacy over conventional CD8 T cells and NK cells

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30

Nanobody‐Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody